CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 7 enrolled
Drug / intervention
Ixekizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04979910
NCT04979910Phase 2Completed
CompareCT.gov

An Experimental Therapeutics Study of a Monoclonal Antibody Against Interleukin 17A in Patients With Treatment-Resistant Depression

Icahn School of Medicine at Mount Sinai·interventional·Posted Jul 28, 2021·Updated May 20, 2025

In Brief

A Phase 2 clinical trial evaluating Ixekizumab for Major Depressive Disorder. Completed, enrolled 7 participants across 1 site.

Detailed Summary

The proposed study aims to test ixekizumab, a monoclonal antibody (mAb) against interleukin 17A (IL-17A), in patients with treatment-resistant depression (TRD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedJul 28, 2021
Enrollment StartAug 27, 2021
Primary CompletionApr 12, 2024
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 4.9 years ago

Interventions

Ixekizumabdrug

a monoclonal antibody (mAb) against interleukin 17A (IL-17A)